Acadia Pharmaceuticals | ACAD - Debt


Acadia Pharmaceuticals reported $56.29M in Debt for its fiscal quarter ending in June of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 56.29M 1.36M Jun/2025
ALKERMES USD 71.6M 1.08M Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Biogen USD 6.29B 1.7M Dec/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Cara Therapeutics USD 0 0 Mar/2025
Corcept Therapeutics USD 6.36M 247K Sep/2025
Cytokinetics USD 1.2B 338.79M Sep/2025
Eisai JPY 236.67B 49.14B Sep/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Incyte USD 40.41M 855K Dec/2025
J&J USD 45.8B 4.97B Sep/2025
Moderna USD 734M 7M Sep/2025
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
Pfizer USD 60.85B 78M Sep/2025
Prothena USD 9.08M 699K Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025